110.49
price down icon0.84%   -0.99
 
loading
Biontech Se Adr stock is traded at $110.49, with a volume of 414.39K. It is down -0.84% in the last 24 hours and up +3.82% over the past month. BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
See More
Previous Close:
$111.48
Open:
$112.21
24h Volume:
414.39K
Relative Volume:
0.42
Market Cap:
$26.57B
Revenue:
$2.97B
Net Income/Loss:
$-812.83M
P/E Ratio:
-32.53
EPS:
-3.3962
Net Cash Flow:
$-1.24B
1W Performance:
-3.54%
1M Performance:
+3.82%
6M Performance:
-8.55%
1Y Performance:
+27.44%
1-Day Range:
Value
$110.54
$113.30
1-Week Range:
Value
$109.52
$115.54
52-Week Range:
Value
$76.53
$131.49

Biontech Se Adr Stock (BNTX) Company Profile

Name
Name
Biontech Se Adr
Name
Phone
-
Name
Address
-
Name
Employee
6,772
Name
Twitter
@BioNTech_Group
Name
Next Earnings Date
2025-03-10
Name
Latest SEC Filings
Name
BNTX's Discussions on Twitter

Compare BNTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BNTX
Biontech Se Adr
110.54 27.11B 2.97B -812.83M -1.24B -3.3962
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.20 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.14 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
342.80 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
605.31 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
300.46 31.87B 3.81B -644.79M -669.77M -6.24

Biontech Se Adr Stock (BNTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-05-25 Reiterated H.C. Wainwright Buy
May-29-25 Initiated Goldman Neutral
Mar-13-25 Initiated Citigroup Buy
Jan-10-25 Initiated Truist Buy
Dec-11-24 Initiated Wells Fargo Overweight
Dec-02-24 Reiterated BMO Capital Markets Outperform
Nov-19-24 Initiated Berenberg Buy
Nov-19-24 Upgrade Evercore ISI In-line → Outperform
Nov-08-24 Upgrade Goldman Neutral → Buy
Sep-24-24 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-17-24 Upgrade Jefferies Hold → Buy
Sep-16-24 Upgrade JP Morgan Underweight → Neutral
Aug-07-24 Upgrade Deutsche Bank Hold → Buy
Aug-02-24 Upgrade HSBC Securities Hold → Buy
May-14-24 Initiated Evercore ISI In-line
Feb-23-24 Initiated BMO Capital Markets Outperform
Jan-05-24 Initiated Oppenheimer Perform
Dec-01-23 Downgrade JP Morgan Neutral → Underweight
Oct-16-23 Downgrade HSBC Securities Buy → Hold
Jul-14-23 Initiated HSBC Securities Buy
May-17-23 Upgrade Redburn Neutral → Buy
Dec-15-22 Upgrade BofA Securities Neutral → Buy
Aug-17-22 Initiated Cowen Market Perform
Jul-13-22 Upgrade SVB Leerink Mkt Perform → Outperform
Jul-06-22 Resumed Canaccord Genuity Buy
Feb-01-22 Upgrade Redburn Sell → Neutral
Dec-16-21 Initiated Morgan Stanley Equal-Weight
Nov-10-21 Upgrade H.C. Wainwright Neutral → Buy
Oct-22-21 Initiated Deutsche Bank Hold
Oct-07-21 Initiated Jefferies Hold
Aug-11-21 Upgrade Bryan Garnier Neutral → Buy
Jul-19-21 Resumed Wolfe Research Outperform
Jun-16-21 Downgrade Redburn Neutral → Sell
May-18-21 Initiated Goldman Neutral
May-11-21 Downgrade Bryan Garnier Buy → Neutral
Dec-01-20 Downgrade BofA Securities Buy → Neutral
Aug-03-20 Resumed Berenberg Buy
Jul-21-20 Upgrade BofA Securities Neutral → Buy
Jun-30-20 Downgrade H.C. Wainwright Buy → Neutral
May-19-20 Upgrade H.C. Wainwright Neutral → Buy
Apr-28-20 Downgrade BofA/Merrill Buy → Neutral
Mar-18-20 Downgrade JP Morgan Overweight → Neutral
Mar-09-20 Initiated H.C. Wainwright Neutral
Jan-24-20 Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20 Downgrade UBS Buy → Neutral
Nov-05-19 Initiated Wolfe Research Outperform
Nov-04-19 Initiated Berenberg Buy
Nov-04-19 Initiated BofA/Merrill Buy
Nov-04-19 Initiated Canaccord Genuity Buy
Nov-04-19 Initiated JP Morgan Overweight
Nov-04-19 Initiated SVB Leerink Outperform
Nov-04-19 Initiated UBS Buy
View All

Biontech Se Adr Stock (BNTX) Latest News

pulisher
04:31 AM

Cancer Vaccine Market Research Service Featuring the Top 5 Developers and Pipeline Activities - GlobeNewswire Inc.

04:31 AM
pulisher
Jul 29, 2025

Best Momentum Stocks to Buy for July 29th - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares Acquired by Kestra Private Wealth Services LLC - Defense World

Jul 29, 2025
pulisher
Jul 27, 2025

Cerity Partners LLC Invests $357,000 in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World

Jul 27, 2025
pulisher
Jul 25, 2025

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union - Ariva

Jul 25, 2025
pulisher
Jul 24, 2025

BioNTech’s Promising Study on Pancreatic Cancer Treatment: Market Implications - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

BioNTech’s New Study on PDAC Treatment: Key Insights for Investors - TipRanks

Jul 22, 2025
pulisher
Jul 20, 2025

BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN

Jul 20, 2025
pulisher
Jul 18, 2025

Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

BioNTech’s BNT327 Trial: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks

Jul 18, 2025
pulisher
Jul 17, 2025

BioNTech’s Promising Lung Cancer Trial: A Potential Game-Changer for NSCLC Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

BioNTech Announces Ryan Richardson to Step Down from the Management Board17.07.25News - Ariva

Jul 17, 2025
pulisher
Jul 16, 2025

BioNTech’s DYNASTY-Breast02 Study: A New Hope for Metastatic Breast Cancer? - TipRanks

Jul 16, 2025
pulisher
Jul 13, 2025

OneDigital Investment Advisors LLC Makes New Investment in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World

Jul 13, 2025
pulisher
Jul 11, 2025

BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment? - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Regeneron and BioNTech’s Promising Lung Cancer Trial: What Investors Need to Know - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target - AInvest

Jul 11, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jul 10, 2025
pulisher
Jul 10, 2025

GAMMA Investing LLC Sells 334 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World

Jul 10, 2025
pulisher
Jul 09, 2025

BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 08, 2025
pulisher
Jul 03, 2025

BioNTech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks

Jul 03, 2025
pulisher
Jul 02, 2025

BioNTech’s Cancer Therapy Study Withdrawn: Implications for Investors - TipRanks

Jul 02, 2025
pulisher
Jul 02, 2025

BioNTech’s BNT151 Study Update: Early Termination and Market Implications - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

BioNTech ADR Earns Relative Strength Rating Upgrade - MSN

Jul 01, 2025
pulisher
Jun 30, 2025

BioNTech’s Latest Clinical Trial: A New Hope for NSCLC Treatment? - TipRanks

Jun 30, 2025
pulisher
Jun 28, 2025

What is HC Wainwright’s Forecast for BioNTech Q3 Earnings? - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

BioNTech ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily

Jun 27, 2025
pulisher
Jun 26, 2025

BioNTech’s Promising Phase II Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jun 26, 2025
pulisher
Jun 26, 2025

BioNTech SE’s Promising Study on Pancreatic Cancer Treatment: What Investors Need to Know - TipRanks

Jun 26, 2025
pulisher
Jun 20, 2025

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Zacks Investment Research

Jun 20, 2025
pulisher
Jun 19, 2025

Equities Analysts Issue Forecasts for BioNTech Q4 Earnings - Defense World

Jun 19, 2025
pulisher
Jun 19, 2025

BioNTech (BNTX) – Analysts’ Recent Ratings Changes - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

HC Wainwright Estimates BioNTech’s Q4 Earnings (NASDAQ:BNTX) - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Market Update: Abercrombie & Fitch Co (ANF) Sees Positive Movement, Closing at 75.00 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Gaining Ground: fuboTV Inc (FUBO) Closes Higher at 3.26, Up 2.84 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Market Resilience: Nerdy Inc (NRDY) Finishes Strong at 1.63, Up 2.52 - DWinneX

Jun 17, 2025
pulisher
Jun 16, 2025

5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga

Jun 16, 2025

Biontech Se Adr Stock (BNTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
biotechnology ONC
$300.65
price down icon 1.59%
$26.90
price up icon 0.82%
$106.97
price up icon 1.95%
$605.62
price up icon 1.18%
$37.27
price up icon 0.08%
Cap:     |  Volume (24h):